Extensively Drug-Resistant Neisseria gonorrhoeae Strain, Canada

by Pill Pals Customer Service | Jun 20, 2025 | News

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released. Author affiliation: Laboratoire de santé publique du Québec, Sainte-Anne-de-Bellevue, Canada...

Next-Generation Sequencing Techniques to Diagnose Culture-Negative Subacute Native Aortic Endocarditis

by Pill Pals Customer Service | Jun 20, 2025 | News

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released. Author affiliation: Geneva University Hospitals Department of Medicine, Geneva, Switzerland...

Genomic Characterization of Leishmania tropica in Cutaneous Leishmaniasis, Somali Region, Ethiopia, 2023

by Pill Pals Customer Service | Jun 20, 2025 | News

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released. Adugna Abera1 , Pieter Monsieurs1, Myrthe Pareyn, Dereje Beyene, Geremew Tasew, Allison...

Internet Pharmacy Warning Letters

by Pill Pals Customer Service | Jun 20, 2025 | News

Report an unsafe online pharmacy to FDAUnsafe online pharmacies offer potentially dangerous prescription drugs to U.S. consumers. FDA has issued warning letters informing the website operators they are engaged in illegal activity in violation of federal law. Buying...

FDA Adds Warning About Serious Risk of Heat-Related Complications

by Pill Pals Customer Service | Jun 20, 2025 | News

AUDIENCE: Patient, Health Care Professional, NeurologyISSUE: The FDA is warning that the antinausea patch Transderm Scōp (scopolamine transdermal system) can increase body temperature and cause heat-related complications, resulting in hospitalization or even death in...

FDA approves tafasitamab-cxix

by Pill Pals Customer Service | Jun 18, 2025 | News

On June 18, 2025, the Food and Drug Administration approved tafasitamab-cxix (Monjuvi, Incyte Corporation) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL). Full prescribing information for Monjuvi will be posted on...